Oxford University Researchers And ProImmune Limited Work Together To Accelerate HIV Vaccine Research

Oxford, UK, 15 June 2005 Scientists in Oxford, developing a vaccine for HIV, hope to be able to accelerate the testing of the vaccine thanks to a donation of vital research reagents by a local Oxford company. ProImmune Ltd, a leading provider of research reagents and services for immune monitoring, has donated reagents based on its Pro5® MHC Pentamer technology to researchers at the MRC Human Immunology Unit for a vaccine development programme. The vaccine is being tested in clinical trials sponsored by the Medical Research Council.

MORE ON THIS TOPIC